$BTAX
Biostax Corp. Stock $btax

$btax Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031773 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$254.7K	$420.9K	$114.6K
YoY Change	73.33%	267.34%	-12.46%
% of Gross Profit
Research & Development	$14.24K
YoY Change
% of Gross Profit
Depreciation & Amortization			$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$268.9K	$420.9K	$0.00
YoY Change	83.02%
Operating Profit		-$420.9K	-$114.6K
YoY Change		267.35%
Interest Expense	-$13.30K	$11.03K	-$32.20K
YoY Change	-71.21%	-134.27%	-103.61%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$2.073M	$2.657M
YoY Change	-100.0%	-178.02%
Pretax Income	-$278.9K	-$2.493M	$3.113M
YoY Change	36.32%	-180.1%	-23.97%
Income Tax
% Of Pretax Income
Net Earnings	-$278.9K	-$2.493M	$3.113M
YoY Change	36.32%	-180.1%	-23.97%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.04	$6.44
Diluted Earnings Per Share	$0.00	-$0.04	$239.6K
COMMON SHARES
Basic Shares Outstanding	82.76M shares	71.08M shares	483.7K shares
Diluted Shares Outstanding		60.09M shares	12.99M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$150.5K	$191.0K	$2.686M
YoY Change	-95.21%	-92.89%	8580.87%
Cash & Equivalents	$150.5K	$185.4K	$29.36K
Short-Term Investments	$0.00	$5.500K	$2.657M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$150.5K	$190.9K	$2.686M
YoY Change	-95.21%	-92.89%	8580.87%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.73K		$0.00
YoY Change			-100.0%
Total Long-Term Assets	$813.2K	$0.00	$0.00
YoY Change			-100.0%
TOTAL ASSETS
Total Short-Term Assets	$150.5K	$190.9K	$2.686M
Total Long-Term Assets	$813.2K	$0.00	$0.00
Total Assets	$963.7K	$190.9K	$2.686M
YoY Change	-69.3%	-92.89%	8467.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.300M	$1.385M	$2.183M
YoY Change	-40.48%	-36.56%	-22.39%
Accrued Expenses	$136.1K	$176.1K	$4.135M
YoY Change	-43.2%	-95.74%	-8.3%
Deferred Revenue
YoY Change
Short-Term Debt	$1.091M	$761.5K	$3.872M
YoY Change	-72.46%	-80.33%	31.78%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.477M	$2.793M	$10.43M
YoY Change	-68.64%	-73.22%	-7.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.477M	$2.793M	$10.43M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.477M	$2.793M	$10.43M
YoY Change	-68.64%	-73.22%	-7.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$383.0M	-$382.7M
YoY Change	0.93%
Common Stock	$380.4M	$380.1M
YoY Change	2.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.513M	-$2.602M	-$7.744M
YoY Change
Total Liabilities & Shareholders Equity	$963.7K	$190.9K	$2.686M
YoY Change	-69.3%	-92.89%	8467.34%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$278.9K	-$2.493M	$3.113M
YoY Change	36.32%	-180.1%	-23.97%
Depreciation, Depletion And Amortization			$0.00
YoY Change			-100.0%
Cash From Operating Activities	$415.1K	-$436.1K	-$93.86K
YoY Change	-3839.19%	364.63%	39.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$500.0K	$0.00
YoY Change
Cash From Investing Activities	-$500.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.00K	350.0K	100.0K
YoY Change	-89.49%	250.01%	88.68%
NET CHANGE
Cash From Operating Activities	415.1K	-436.1K	-93.86K
Cash From Investing Activities	-500.0K	0.000
Cash From Financing Activities	50.00K	350.0K	100.0K
Net Change In Cash	-34.95K	-86.09K	6.140K
YoY Change	-107.52%	-1502.12%	-142.85%
FREE CASH FLOW
Cash From Operating Activities	$415.1K	-$436.1K	-$93.86K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001559356
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent		usd
CY2022Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi		usd
CY2022Q3	IMUN	Undocumented Investor Advances Current UndocumentedInvestorAdvancesCurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022Q3	IMUN	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense		usd
CY2021Q3	IMUN	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense		usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q3	IMUN	Receipt Of Common Shares ReceiptOfCommonShares		usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	IMUN	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
	IMUN	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense		usd
	IMUN	Gain Recognized Upon Receipt Of Common Stock GainRecognizedUponReceiptOfCommonStock		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	IMUN	Reclassification To Notes Payable From Accrued Interest ReclassificationToNotesPayableFromAccruedInterest		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54933
	dei	Entity Registrant Name EntityRegistrantName	IMMUNE THERAPEUTICS, INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3226705
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2431 Aloma Ave.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 124
	dei	Entity Address City Or Town EntityAddressCityOrTown	Winter Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32792
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	613-8802
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82762035	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	185447	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	493885	usd
CY2022Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	5500	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2645000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	190947	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	3138885	usd
CY2022Q3	us-gaap	Assets Assets	190947	usd
CY2021Q4	us-gaap	Assets Assets	3138885	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1385007	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2184848	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	114567	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	671481	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3138885	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3070208	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	420862	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3421176	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	176057	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	239558	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	134678	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	564300	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	90000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	891420	usd
CY2021Q4	IMUN	Undocumented Investor Advances Current UndocumentedInvestorAdvancesCurrent	715631	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2793225	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11087141	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2793225	usd
CY2021Q4	us-gaap	Liabilities Liabilities	11087141	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82198697	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82198697	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	483714	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	483714	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	8220	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	49	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380068768	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	371473810	usd
CY2022Q3	IMUN	Stock Issuances Due StockIssuancesDue	10303	usd
CY2021Q4	IMUN	Stock Issuances Due StockIssuancesDue	10303	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382689569	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-379432418	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2602278	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	190947	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	894596	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	438583	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	152667	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	420862	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	114567	usd
	us-gaap	Operating Expenses OperatingExpenses	894596	usd
	us-gaap	Operating Expenses OperatingExpenses	591250	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-420862	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-114567	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-894596	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60089305	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	483714	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-591250	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20643181	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.86
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6202919	usd
	IMUN	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense	3165151	usd
CY2022Q3	IMUN	Gain Loss On Settlement Of Obligations And Conversion Of Debt GainLossOnSettlementOfObligationsAndConversionOfDebt	-1467271	usd
CY2021Q3	IMUN	Gain Loss On Settlement Of Obligations And Conversion Of Debt GainLossOnSettlementOfObligationsAndConversionOfDebt	603204	usd
	IMUN	Gain Loss On Settlement Of Obligations And Conversion Of Debt GainLossOnSettlementOfObligationsAndConversionOfDebt	-1169691	usd
	IMUN	Gain Loss On Settlement Of Obligations And Conversion Of Debt GainLossOnSettlementOfObligationsAndConversionOfDebt	711896	usd
CY2021Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3105000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2645000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3105000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	594288	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
CY2021Q3	IMUN	Receipt Of Common Shares ReceiptOfCommonShares	5761500	usd
	IMUN	Receipt Of Common Shares ReceiptOfCommonShares	5761500	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	11034	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	32197	usd
	us-gaap	Interest Expense InterestExpense	107102	usd
	us-gaap	Interest Expense InterestExpense	164731	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1178230	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2072593	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3227507	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2362555	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4381895	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2493455	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	3112940	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
	us-gaap	Net Income Loss NetIncomeLoss	3790645	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	482527	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60089305	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12990932	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20643181	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12989745	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-11666981	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	56480	usd
	IMUN	Adjustments To Additional Paid In Extinguishment Of Derivative Liability Upon Conversion Of Debt AdjustmentsToAdditionalPaidInExtinguishmentOfDerivativeLiabilityUponConversionOfDebt	76211	usd
	us-gaap	Net Income Loss NetIncomeLoss	3790645	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-7743645	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0204	pure
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	698324	usd
	IMUN	Adjustments To Additional Paid In Charge Resulting From Warrant Modification AdjustmentsToAdditionalPaidInChargeResultingFromWarrantModification	1605913	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	95973	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2602278	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2602278	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
	us-gaap	Net Income Loss NetIncomeLoss	3790645	usd
	IMUN	Gain On Issuance Of Forte License GainOnIssuanceOfForteLicense	3165151	usd
	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	-1169691	usd
	IMUN	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	711896	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2645000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3105000	usd
	IMUN	Gain Recognized Upon Receipt Of Common Stock GainRecognizedUponReceiptOfCommonStock	5761500	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1178230	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	34789	usd
	IMUN	Increase Decrease In Deposit IncreaseDecreaseInDeposit	-5500	usd
	IMUN	Increase Decrease In Deposit IncreaseDecreaseInDeposit	200	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-75895	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	102177	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4620	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-20244	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	270001	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	116929	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	129943	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-35321	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	18499	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-996865	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-220616	usd
	IMUN	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances	6369	usd
	IMUN	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances	240000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	265000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	417058	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	688427	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	240000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-308438	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19384	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	493885	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9971	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	185447	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29355	usd
	IMUN	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	6901242	usd
	IMUN	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	56480	usd
	us-gaap	Stock Issued1 StockIssued1	95973	usd
	IMUN	Reclassification To Notes Payable From Accrued Interest ReclassificationToNotesPayableFromAccruedInterest	243568	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3790645	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	483714	shares
CY2022Q3	us-gaap	Cash Cash	185447	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2602278	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
	us-gaap	Net Income Loss NetIncomeLoss	3790645	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	81615483	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_z8Vi1dlzX49a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zf8DTIcwDkl8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zPCOFRy2xTF1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zuv8BqpLexc4">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20220930_zobHbpKPfKf6" title="Cash at federal deposit">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	482527	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	7.86
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3112940	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3790645	usd
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	483714	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	482527	shares
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12507218	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12507218	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12990932	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12989745	shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3112940	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	4.36	pure
CY2022Q3	us-gaap	Notes Payable NotesPayable	671481	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	3070208	usd
CY2022Q3	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	375000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	548306	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	20057156	shares
CY2021Q4	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	5.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	2283850	shares
	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice	126.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	17225000	shares
	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice	0.05
	IMUN	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice	0.05
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	548306	shares
CY2022Q3	IMUN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	8.39
	IMUN	Charge Resulting From Warrant Modification ChargeResultingFromWarrantModification	1605913	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y7M17D
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q3	IMUN	Cash Payment CashPayment	500000	usd
	IMUN	Cash Payment Description CashPaymentDescription	In consideration for the license, the Company will provide (i) a non-refundable cash payment of $500,000 within ninety (90) days of September 30, 2022, (ii) a non-refundable cash payment of $500,000 at the earliest of either the National Agency for Food and Drug Administration and Control (“NAFDAC”) approval for JKB-122 in Africa for any indication, or the enrollment of the first patient in a Food and Drug Administration (“FDA”) trail for Crohn’s Disease, (iii) 250,000 shares of common stock of the Company within sixty (60) days of September 30, 2022, (iv) an annual payment of $100,000 each anniversary of the date of the agreement until the Company gains regulatory approval in Africa, (v) milestone payments (described below), and (vi) royalties on net sales. The 250,000 shares of common stock represent approximately 0.32% of the currently outstanding common stock of the Company.
	IMUN	Description For Monthly Interest For Payment DescriptionForMonthlyInterestForPayment	the payment amount will bear the lower of (i) 1.5% interest per month or (ii) the maximum rate allowed by law, to be compounded quarterly. The interest will accrue beginning on the first day after the payment is due.

Files In Submission

Name	View Source	Status
0001493152-22-031773-index-headers.html	Edgar Link	pending
0001493152-22-031773-index.html	Edgar Link	pending
0001493152-22-031773.txt	Edgar Link	pending
0001493152-22-031773-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
imun-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
imun-20220930_cal.xml	Edgar Link	unprocessable
imun-20220930_def.xml	Edgar Link	unprocessable
imun-20220930_pre.xml	Edgar Link	unprocessable
imun-20220930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTAX
Biostax Corp. Stock $btax

2022 Q4 Form 10-Q Financial Statement

#000149315222031773 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX Biostax Corp. Stock $btax

2022 Q4 Form 10-Q Financial Statement

#000149315222031773 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX
Biostax Corp. Stock $btax